Merck's Zolina shows antitumor activity; PolyMedix gets $14M;

 @FierceBiotech: Explosion of cancer drug trials spurs a new approach. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion is looking for $35M out of an IPO this week. The strategy: Aim real low and keep your fingers crossed. Article | Follow @JohnCFierce

> According to research published in The Lancet, Merck's cancer drug Zolina shows promising antitumor activity and is well tolerated when combined with short-term palliative radiotherapy in patients with advanced pelvic cancer. Article

> Ambrilia Biopharma and its subsidiary Cellpep Pharma have approved a proposed transaction in which Ambrilia and Cellpep would receive additional non-dilutive financing through the disposition of a limited partnership interest. Before expenses to be incurred in connection with this potential transaction, a gain in the amount of approximately $4M could be realized by Ambrilia and Cellpep upon the closing. Ambrilia release

> Hercules Technology Growth Capital will provide PolyMedix $14 million in credit facilities. PolyMedix anticipates that proceeds from the facility may be used to fund certain Phase III enabling activities for its two lead compounds, PMX-60056 and PMX-30063, including manufacturing and toxicology studies, as well as for other general corporate purposes. Release

> Roche's Genentech is just weeks away from starting to ramp up production at its $400 million campus in Hillsboro, Oregon. Report

And Finally... An analysis of dietary data from more than 400,000 men and women found only a weak association between high fruit and vegetable intake and reduced overall cancer risk. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.